INTRODUCTION
Evidence from a variety of sources suggests that circulating complexes of DNA antigen and anti-DNA antibody are of primary importance in the immunopathogenesis of renal injury in systemic lupus erythematosus (SLE).' Increased titers of both antinative DNA (nDNA) and antisingle strand DNA (sDNA) are correlated with clinical activity and hypocomplementemia (1) (2) (3) . Both nDNA and sDNA alternate with specific antibody in the circulation (1, 4) . DNA antigen has been detected by immunofluorescence techniques in the same distribution along the glomerular basement membrane as gammaglobulin and complement components (5, 6) . Polynucleotide immune complexes, chiefly involving antibody to sDNA and nDNA, are highly enriched relative to serum levels in acid buffer or deoxyribonuclease eluates of isolated glomeruli from severely nephritic kidneys of patients with SLE (5, (7) (8) (9) and in serum cryoprecipitates (10) . Additional evidence for the presence of complexes of DNA and anti-DNA in the cir-culation derives from the demonstration of increased anti-DNA activity after digestion of serum with deoxyribonuclease (11, 12) .
In the present investigation the avidity of anti-DNA antibody in serum, glomerular eluates, and cryoprecipitates of patients with SLE was estimated to define further the qualitative characteristics of anti-DNA having greatest potential for immune complex tissue injury. The data suggest that antinative DNA of high avidity is involved primarily.
METHODS
Patients and sera. Patients studied were receiving medical therapy at the Rockefeller University Hospital (22 patients) or at the University of Virginia Hospital (10 patients Glomerular eluates. Glomeruli were isolated from autopsy kidneys from patients with severe SLE glomerulonephritis, as described previously (9) . Eluates were prepared by treating the glomeruli with deoxyribonuclease, followed by concentration of the eluate immunoglobulin by precipitation with 50% saturated ammonium sulfate. The eluates contained only IgG by gel diffusion analysis with appropriate antisera, and were inactivated by heating at 56°C for 30 min before use.
Cryoprecipitates. Cryoprecipitates were isolated from serum, thoroughly washed, and resolubilized in phosphate buffered saline at 370C, as described in detail previously (10) .
DNA. DNA intrinsically-labeled with [3H]thymidine was prepared from HeLa cells (14) . An operationally native DNA preparation was obtained by chromatography of 3H-HeLa DNA on methylated albumin-kieselguhr columns (15) (16) (17) . 92% of the DNA was eluted from the column with 0.9 M NaCl. Specific activity of the 0.9-M NaCl fraction was -100,000 cpm/,g. The 260:280 ratio was 1.96. Based upon the following criteria, this material was considered to be nDNA: (a) an aliquot was rechromatographed on methylated albumin-kieselguhr by using both linear and stepwise NaCl gradients and eluted exclusively in the 0.9-M NaCl fraction; (b) failure to react antigenically with rabbit antiserum to sDNA or with various human disease sera having anti-sDNA but not anti-nDNA. sDNA was prepared before each experiment by boiling an aliquot of the above nDNA for 10 min followed by immediate cooling in an ice bath. This material was reactive with both rabbit and human anti-sDNA antibodies.
Measurement of anti-DNA antibodies. Anti-DNA antibodies were determined by a quantitative ammonium sulfate precipitation radioimmunoassay (Farr Assay) as previously described (17) . 25 ,l of serum was combined with 75 ,ul of 3H-HeLa DNA in 0.15 M NaCl, 0.03 M borate buffer, pH 7.85 and incubated for 1 h at 370C and then for 16 h at 4°C. 100 ,ul of cold 70%o saturated ammonium sulfate was added. After 2 h at 4°C, this mixture was centrifuged for 10 min at 15,000 rpm in a Beckman microfuge. (Beckman Instruments, Inc., Cedar Grove, N.J.) Radioactivity in the supemate was determined with a liquid scintillation counter.
Certain technical modifications of this assay optimized detection of anti-DNA antibody and minimized nonspecific precipitation of DNA. All antibody test samples were heatinactivated at 56°C before use. This procedure and the use of high ionic strength, alkaline pH, and a low borate concentration largely eliminate Clq and other nonspecific protein-DNA interactions (18) . The prolonged 40C incubation of DNA with test sera was included to maximize DNA binding by less avid antibody not detected at 370C. All dilutions of test samples were prepared in borate-saline buffer containing 5% bovine serum albumin. This normalized the protein concentration in the samples and prevented the artifactual increase in DNA binding occasionally seen with very dilute serum samples.
By using the conditions detailed above, the mean percent binding of nDNA (10 ng per assay) by undiluted sera from 25 normal individuals was 9.7%+SD of 7.7%; sDNA binding by these sera was 11.6±9.2%. Additional controls included in each assay were several dilutions of a serum from a patient with SLE having high levels of anti-DNA antibody, a normal serum lacking antibody, and diluent alone. The nDNA preparation was examined periodically for development of sDNA determinants by performing assays with sera containing only anti-sDNA antibody. Quantitative data concerning relative anti-DNA antibody levels in the SLE sera were obtained by calculating the 50%o antigen-binding capacity (ABC) in ,ug DNA/ml serum, using a test antigen concentration of 25 ng per assay.
Measurement of anti-DNA avidity. Anti-DNA avidity was estimated by performing Farr assays in duplicate upon appropriately diluted sera, glomerular eluates, or cryoprecipitates by using five different antigen concentrations over a 40-fold range (5 ng-200 ng 3H-HeLa DNA). Dilutions of antibody chosen for the avidity measurements bound approximately 50% of 25 ng of nDNA or sDNA in the asays and were used to minimize the effect of antibody concentration upon avidity estimation by the Farr technique (19) . Avidity was calculated from plots of the reciprocals of bound, b, and free, c, antigen according to the Sips distribution formula (20) . Radioactivity in cpm was used to quantitate free and bound antigen. The Y-intercept, which is a measure of the total number of binding sites with extrapolation of 1/c to zero ("infinite antigen concentration"), ranged from 0.2 to 0.4 x 10-3) suggesting that the antibody concentrations were appropriately normalized by the dilutions chosen for these measurements. With the antigen concentrations used, the plots of 1/b vs. 1/c were generally linear. With several antibody preparations, curvature of the plot 1/b vs. 1/ca toward the abscissa at higher antigen concentrations was corrected by choosing a value less than 1 for the exponent, a, (a is the index of heterogeneity).
To establish the precision of the method for estimating avidity, independent assays were performed five times with two sera. The standard deviation was 18% or less of the calculated mean avidity. nounced association between sDNA binding and disease activity also obtained. Low levels of antibody reactive with sDNA could still be detected in the sera of patients with inactive disease, however. Significant differences in anti-DNA avidity were observed in the three groups (Table I , II, and III). The relative anti-nDNA avidity in patients with active glomerulonephritis was 0.29±0.04. The mean avidity of anti-nDNA antibodies in Group 2 patients without glomerulonephritis was significantly higher, 1.09±0.21 (P < 0.001). The avidity of antibody reactive with sDNA antibody did not differ among the three groups.
Studies on SLE glomerular eluates. The anti-DNA activity in IgG eluted from glomeruli isolated from SLE glomerulonephritic kidneys by deoxyribonuclease digestion was characterized in the same fashion as serum. Eluates from kidneys of four patients who died with advanced glomerulonephritis contained sufficient antibody to nDNA for affinity estimations (Table  IV) . In contrast to serum antibody in patients with active glomerulonephritis, which was of relatively low avidity, the avidity of anti-nDNA antibody in the eluates was more than 10-fold higher (mean±SEM = 3.51±1.21; P < 0.001). Note that avidity of antinDNA in sera from patients with active SLE without glomerulonephritis was intermediate between that of serum antibody in patients with active glomerulonephritis and that of the glomerular eluates. Further evidence for a marked difference between avidity of anti-nDNA in serum and glomerular eluates was provided by study of patient Rus. Anti-nDNA avidity in serum drawn during a period of active glomerulonephritis before death was 0.25. Avidity of anti-nDNA in IgG eluted from her kidneys after death was 4.20.
The possibility that nonspecific binding by nonimmunoglobulin proteins in serum might account for the relatively higher avidity of antibody in the eluates was examined by comparing the avidity of several sera with that obtained with isolated IgG. Significant differences were not seen. Thus, for patient San, anti-nDNA avidity was 0.21 and 0.23 for whole serum and isolated IgG, respectively; similary, the avidity for anti-nDNA in Ayl serum, 0.51, was virtually identical to that for Ayl IgG, 0.47.
Studies on DNA antibodies in cryoprecipitates.
Anti-nDNA avidity was estimated in five cryoprecipitates from patients with active SLE, two of whom had glomerulonephritis (Table V) . The mean anti-nDNA avidity of cryoprecipitates was 0.71±0.12, a value not significantly different from that in the supernatant serum, 0.54+0.18. Low avidity anti-nDNA was found in the cryoprecipitate of one patient, Smi, in the absence of detectable antibody in serum.
Anti-DNA binding curve slope as an estimate of avidity. Calculation of binding curve slopes for anti-DNA with nDNA or sDNA as ligands did not provide avidity data which correlated with the values estimated from the Sips distribution formula. The major limitation of the slope method was related primarily to the marked influence on the binding curve slope of differences in antigen-antibody ratio in the assay reaction mixtures. The pronounced effect of antigen concentration on the slope of the 3H-nDNA binding curve is illustrated in Fig. 1 . In this experiment, dilutions of a single serum were assayed simultaneously against five concentrations of DNA. The slope for the highest concentration, 52 ng, was 82.5, and for the lowest concentration, 5 ng, was 19.4.
The influence of antigen concentration on the bind- The levels of anti-nDNA antibodies in the serum correlated particularly well with differences in patient clinical status, the highest levels being seen in patients with active nephritis. These findings are in agreement with earlier data supporting a strong association between increased anti-nDNA antibody in serum and renal injury in SLE (1-3) .
The present data are interpreted as implicating high avidity anti-nDNA antibody as the species primarily responsible for DNA-anti-DNA immune complex-induced renal injury. This reasoning is based upon the following considerations. First, the highest avidity anti-DNA was localized to IgG eluted from glomerulonephritic kidneys, i.e. from the actual site of tissue injury. Second, anti-nDNA of lowest avidity was found in the serum of patients with active glomerulonephritis. The most likely explanation for these findings is the removal from the circulation of higher avidity antinDNA by DNA.
The intermediate avidity of anti-nDNA in the serum of patients with active disease but not having nephritis can also be interpreted in terms of this conceptual framework by postulating a smaller DNA antigenic load in the circulation of these patients. In this group, increased anti-nDNA of relatively higher avidity was found. If the release of DNA into the circulation was either brief in duration or very low quantitatively, the measureable avidity of detectable antibody would be higher because less of the very high avidity antibody would be removed by antigen. Decreased magnitude of the clinical sequelae of pathogenetically sig-nificant DNA-anti-DNA immune complex formation would be expected in the groups, as was in fact observed: less severe hypocomplementemia and absence of clinical nephritis.
Although cryoprecipitates in SLE are highly enriched relative to serum for anti-DNA antibody activity (10) , high avidity antibody was not found in most cryoprecipitates. These limited data thus provide additional evidence that high avidity antibodies are removed quickly from the circulation by DNA.
Of considerable interest was the observation that the avidity ofserum antibody to sDNA did not differ among the three clinical groups. The explanation for this finding is unclear. As free sDNA has been demonstrated by hemagglutination in the serum of patients with SLE (4), an effect of circulating antigen upon measureable anti-sDNA affinity similar to that postulated for anti-nDNA might be expected. It is possible that binding of sDNA in vivo to nonimmunoglobulin serum proteins, such as Clq, influences anti-sDNAsDNA interaction in this regard.
Alternatively, the actual anti-sDNA avidity in sera of patients with active nephritis may be in fact relatively lower than in patients without nephritis. Here the higher measured avidity of antibody reactive with sDNA could represent a major contribution of antinDNA. A generally greater reactivity of anti-nDNA with sDNA relative to nDNA has been defined clearly in hemagglutination inhibition experiments (3) . The present observations are in general agreement with those in the New Zealand mouse model of immune complex glomerulonephritis and in human SLE in which low avidity anti-DNA antibodies in the serum have been related to the occurrence of nephritis (22, 23) . In these studies, time of onset, course, and severity of nephritis were associated with the presence of increasing levels of low avidity anti-DNA in serum. Avidity was estimated by measuring the rate of dissociation of 1251-DNA/anti-DNA complexes in the presence of a large excess of unlabeled DNA. The data were interpreted as indicating that low avidity antibody, which is less efficient in immune elimination of antigen than high avidity antibody (24) , favors persistence of immune complexes which can be deposited in tissues. This concept regarding the pathogenicity of low avidity antibody is not consistent with the present data indicating high avidity anti-nDNA as the species deposited along the renal glomerular basement membrane.
The present data do not agree with those of a recent report in which the slope of the DNA binding curve was used to examine anti-DNA avidity and its relationship to glomerulonephritis (21) . In this study serum from patients with glomerulonephritis gave steeper DNA binding slopes than serum from patients without glomerulonephritis. The results were interpreted as indicating an association of high avidity serum anti-DNA with nephritis. Determination of the slopes of sDNA and nDNA binding curves in the present investigation revealed considerable variation among individual patients, but no significant differences between groups. Furthermore, there was no correlation between the DNA binding slope and avidity estimated from the Sips plots either for individual patients or for patient groups. As uncharacterized DNA which had not been subjected to procedures removing sDNA contamination was used in the previous study, it is probable that the avidity of both nDNA and sDNA specific antibody was being measured simultaneously. Variation in the proportion of anti-nDNA and anti-sDNA in the sera relative to a constant mixture of sDNA and nDNA in the assay could give, therefore, apparent differences in avidity. As demonstrated in the present study, the slope of the antigen binding curve is highly dependent upon the amount of available antigen, becoming sharply steeper with increasing antigen: antibody ratios. As patients without nephritis generally have a greater portion of anti-sDNA relative to antinDNA, minor contamination of the DNA used as ligand in the bindinig assay results in a decreased slope.
A number of unanswered questions remain. Given that high avidity antibody to native DNA is the species leading to DNA-anti-DNA complexes with optimum potential for renal injury, what is the nature of the complex itself. This system generally is associated with active glomerulonephritis when anti-DNA antibody exists in excess relative to antigen, a situation opposite to that in serum sickness models of glomerulonephritis with heterologous albumin as the antigen (25) 
